Serina SVP granted 85,558 stock options

Serina Therapeutics, Inc. reported that SVP, CMC & Formulation Tenjarla Srini received a grant of stock options covering 85,558 shares of common stock.

Rhea-AI Filing Summary

Serina Therapeutics, Inc. reported that SVP, CMC & Formulation Tenjarla Srini received a grant of stock options covering 85,558 shares of common stock. The options have an exercise price of $1.89 per share and expire on May 21, 2036.

According to the vesting terms, 12/48ths of the options vest 12 months after the vesting commencement date, and 1/48th vests monthly thereafter until fully vested. Following this grant, Srini holds 85,558 derivative securities directly, reflecting a routine compensation-related award rather than an open-market trade.

Insider Trade Summary

Grant/Award: 85,558 shares

Grant/Award 1 txn

Insider Tenjarla Srini

Role SVP, CMC & Formulation

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	85,558	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 85,558 contracts (Direct)

Footnotes (1)

1. F1. Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested.

Key Figures

Options granted: 85,558 options Exercise price: $1.89 per share Total options after grant: 85,558 options +3 more

6 metrics

Options granted 85,558 options Stock Option (right to buy) grant to SVP

Exercise price $1.89 per share Conversion or exercise price for granted options

Total options after grant 85,558 options Total derivative securities following transaction

Expiration date May 21, 2036 Option expiration for this grant

Initial vesting cliff 12/48ths after 12 months First vesting event after vesting commencement date

Ongoing vesting rate 1/48th monthly Monthly vesting after initial 12-month period

Key Terms

Stock Option (right to buy), conversion or exercise price, vesting, derivative securities, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

conversion or exercise price financial

"conversion_or_exercise_price: 1.8900"

vesting financial

"shares subject to the option shall vest twelve months after the Vesting Commencement Date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

derivative securities financial

"total_shares_following_transaction: 85558.0000 (derivative transaction)"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Serina Therapeutics (SER) insider Tenjarla Srini report in this Form 4?

Tenjarla Srini reported receiving a stock option grant for 85,558 shares of Serina Therapeutics common stock. The award is compensation-related, giving the executive the right to buy shares at a fixed price if vesting conditions are met over time.

What is the exercise price of the new Serina Therapeutics (SER) stock options?

The granted stock options have an exercise price of $1.89 per share. This means Srini can purchase up to 85,558 Serina Therapeutics shares at $1.89 each once the options vest, regardless of the future market price at exercise.

How do the Serina Therapeutics (SER) options granted to Tenjarla Srini vest over time?

The options vest gradually based on time. Twelve forty-eighths of the shares vest 12 months after the vesting commencement date, with one forty-eighth vesting monthly thereafter, until 100% of the 85,558 optioned shares are fully vested.

When do the newly granted Serina Therapeutics (SER) stock options expire?

The stock options granted to Tenjarla Srini expire on May 21, 2036. If any options remain unexercised by that expiration date, they lapse and can no longer be used to purchase Serina Therapeutics common shares.

Is this Serina Therapeutics (SER) Form 4 a market purchase or sale of shares?

No, this Form 4 reflects a grant of stock options as compensation, not a market trade. Srini acquired derivative rights to buy shares at $1.89, and no open-market buying or selling of common stock is reported in this filing.

How many Serina Therapeutics (SER) derivative securities does Srini hold after this grant?

After this grant, Tenjarla Srini directly holds 85,558 derivative securities in the form of stock options. These options each relate to one share of Serina Therapeutics common stock, subject to the time-based vesting schedule and the 2036 expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/26/2026 - 07:44 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tenjarla Srini

(Last) (First) (Middle)

601 GENOME WAY, SUITE 2001

(Street)

HUNTSVILLE ALABAMA 35806

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CMC & Formulation

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.89	05/21/2026		A		85,558		(1)	05/21/2036	Common Stock	85,558	$0	85,558	D

Explanation of Responses:

1. Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested.

Remarks:

	/s/ Srini Tenjarla	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)